To include your compound in the COVID-19 Resource Center, submit it here.

IMC-C225: Began Phase II trial

ImClone Systems Inc. (IMCL), New York, N.Y.
Product: IMC-C225
Business: Cancer
Therapeutic category:

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE